Axovant Sciences Ltd. (AXON) Analysts See $-0.39 EPS as of June, 12

May 17, 2018 - By Elizabeth Jones

Axovant Sciences Ltd. (NASDAQ:AXON) Corporate Logo

On June, 12 WallStreet anticipated Axovant Sciences Ltd. (NASDAQ:AXON)’s earnings report, according to RTT. Analysts expect change of 26.42 % or $0.14 from previous year’s $-0.53 earnings per share compared to current’s $-0.39 earnings per share. The stock increased 5.98% or $0.07 during the last trading session, touching $1.24.Axovant Sciences Ltd. has volume of 448,778 shares. Since May 17, 2017 AXON has declined 90.77% and is downtrending. AXON underperformed the S&P 500 by 102.32%.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe.The firm is valued at $133.66 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer??s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.Currently it has negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Axovant Sciences Ltd. (NASDAQ:AXON) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.